Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Rinvoq | upadacitinib | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rinvoq | upadacitinib | Crohns disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rituxan | Rituximab | Acute Lymphoblastic Leukemia | Do not reimburse | Complete | ||
| Rituxan | Rituximab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Rituxan | Rituximab | Granulomatosis with polyangiitis and microscopic polyangiitis | List with clinical criteria and/or conditions | Complete | ||
| Rosiver | Ivermectin | Rosacea | List with criteria/condition | Complete | ||
| Rozlytrek | Entrectinib | ROS1-positive NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rozlytrek | entrectinib | Extracranial solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rukobia | fostemsavir | Human immunodeficiency virus type 1 (HIV-1) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ruzurgi | amifampridine | Lambert-Eaton myasthenic syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ryaltris | olopatadine hydrochloride and mometasone | Seasonal allergic rhinitis | Received | |||
| Rybelsus | semaglutide | diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rybrevant | amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Received | |||
| Rybrevant | amivantamab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rydapt | Midostaurin | Systemic Mastocytosis | Do not reimburse | Complete | ||
| Rydapt | Midostaurin | Acute Myeloid Leukemia | Reimburse | Complete | ||
| Rylaze | crisantaspase recombinant | Acute lymphoblastic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Samsca | Tolvaptan | Hyponatremia, non-hypovolemic | Do not list | Complete | ||
| Saphnelo | anifrolumab | Systemic lupus erythematosus | Reimburse with clinical criteria and/or conditions | Complete | ||
| Saphris | Asenapine | Schizophrenia | Do not list | Complete | ||
| Saphris | Asenapine | Bipolar I disorder | List with clinical criteria and/or conditions | Complete | ||
| Sarclisa | Isatuximab | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Sarclisa | isatuximab | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Sativex | Delta-9-tetrahydrocannabinol/cannabidiol | Pain, Neuropathic (adjunctive) in MS. | Do not list | Complete | ||
| Sativex | Delta-9-tetrahydrocannabinol/cannabidiol | Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids) | Do not list | Complete |
Last Updated : June 30, 2024